Linshom fills the $1.2B need (annual) for patients at risk of respiratory depression that require continuous respiratory monitoring (CRM). Current technology in the OR and ICU is not transferable and fails at this critical task. Linshom’s portable respiratory monitor meets the growing mandate for CRM for all post surgical patients; particularly those receiving opioids, suffering from apnea, or requiring supplemental oxygen.